Spero Therapeutics Inc. Common Stock (SPRO)
Stock · NASDAQ · Health Care
$1.1as of 10/16/2026
Price chart
Active signals
SPRO Signal Track Record
How signals performed across all stocks →What SPRO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -0.9% | 45% | September 23, 2026 |
| Bollinger Band Breakdown | 25 | 0.0% | 48% | September 9, 2026 |
| Bollinger Band Breakout | 21 | -6.4% | 43% | September 22, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +2.8% | 60% | March 23, 2026 |
| Any 20-session window (baseline) | -3.2% | 38% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for ad…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 25
- Website
- sperotherapeutics.com/
Fundamentals
- 1-day range
- $1.09$1.17
- Market cap
- $73.53M
- P/E (trailing)
- 8.91
- P/E (forward)
- -0.99
- EPS (trailing)
- $0.04
- Dividend yield
- —
- Beta
- 1.54
- Avg. volume
- 976.3K
How Spero Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Spero Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SPROSpero Therapeutics Inc. Common Stock$1.1▼ 2.65%Market cap $73.53MP/E 8.91$1.08$3.08
- ACETAdicet Bio Inc. Common Stock$4.57▼ 11.09%Market cap $74.13MP/E —$4.8$17.04
- TLPHTalphera Inc. Common Stock$1.08▲ 0.93%Market cap $74.22MP/E —$0.6866$1.57
- OSTXOS Therapies Incorporated Common Stock$1.32▼ 6.38%Market cap $74.23MP/E —$1.15$2.25
- ACRVAcrivon Therapeutics Inc. Common Stock$1.64▼ 6.82%Market cap $72.33MP/E —$1.27$3.56
- ELTXElicio Therapeutics Inc. Common Stock$1.56▼ 12.36%Market cap $72.28MP/E —$1.71$16
- CYPHCypherpunk Technologies Inc. Common Stock$2.57▼ 14.90%Market cap $71.74MP/E —$0.393$4.19
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SPRO Spero Therapeutics Inc. Common Stock | $73.53M | 8.91 | $1.1 | ▼ 2.65% | $1.08$3.08 |
| ACET Adicet Bio Inc. Common Stock | $74.13M | — | $4.57 | ▼ 11.09% | $4.8$17.04 |
| TLPH Talphera Inc. Common Stock | $74.22M | — | $1.08 | ▲ 0.93% | $0.6866$1.57 |
| OSTX OS Therapies Incorporated Common Stock | $74.23M | — | $1.32 | ▼ 6.38% | $1.15$2.25 |
| ACRV Acrivon Therapeutics Inc. Common Stock | $72.33M | — | $1.64 | ▼ 6.82% | $1.27$3.56 |
| ELTX Elicio Therapeutics Inc. Common Stock | $72.28M | — | $1.56 | ▼ 12.36% | $1.71$16 |
| CYPH Cypherpunk Technologies Inc. Common Stock | $71.74M | — | $2.57 | ▼ 14.90% | $0.393$4.19 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- Gapping stocks in Tuesday's sessionChartMill · 9/22/2026
- Meta Platforms To $650? Here Are 10 Top Analyst Forecasts For MondayBenzinga · 9/14/2026
- HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $6Benzinga · 9/14/2026
Insider Activity
Insider Actions →- Zack Debra · August 3, 2026 · Grant162.3K
- Zack Debra · August 3, 2026 · Grant324.7K
- Tregoning Kathleen · June 23, 2026 · Grant20.0K
- Tregoning Kathleen · June 23, 2026 · Grant10.0K
- Smith Cynthia · June 23, 2026 · Grant20.0K
- Smith Cynthia · June 23, 2026 · Grant10.0K
- Jackson Scott Thomas · June 23, 2026 · Grant20.0K
- Jackson Scott Thomas · June 23, 2026 · Grant10.0K
- VINK PATRICK V.J.J. · June 23, 2026 · Grant20.0K
- VINK PATRICK V.J.J. · June 23, 2026 · Grant10.0K
- Deshpande Milind · June 23, 2026 · Grant20.0K
- Deshpande Milind · June 23, 2026 · Grant10.0K
- Pottage John C Jr · June 23, 2026 · Grant20.0K
- Pottage John C Jr · June 23, 2026 · Grant10.0K
- THOMAS FRANK E · June 23, 2026 · Grant20.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 20.53M
- Total value held
- $47.36M
- Institutional holders
- 47
- Unknown9.19M
- Unknown2.36M
- Unknown1.80M
- Unknown1.19M
- Unknown890.0K
- Unknown885.6K
- Unknown519.9K
- Unknown433.2K
- Unknown425.7K
- Unknown422.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
SPRO among stocks that gapped in Tuesday's session
Spero Therapeutics was listed as a gapping stock on Tuesday, meaning its price opened significantly different from the previous close. Such gaps often reflect a quick shift in market sentiment. The move occurs while the stock is near its $1.19 support level and has a neutral RSI around 49.
SPRO among stocks that gapped in Tuesday's session. Spero Therapeutics was listed as a gapping stock on Tuesday, meaning its price opened significantly different from the previous close. Such gaps often reflect a quick shift in market sentiment. The move occurs while the stock is near its $1.19 support level and has a neutral RSI around 49.